Smoking Cessation in Patients After Coronary Angiography
NCT ID: NCT04784702
Last Updated: 2021-03-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
122 participants
OBSERVATIONAL
2014-08-05
2017-01-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
BACKGROUND Cigarette smoking is a major risk factor of coronary artery disease (CAD). Smoking cessation is one of the most cost-effective intervention in lifestyle. Self-reported rates of smoking cessation are reasonably low. Cytisine is promising drug in support of smoking cessation. Smoking affects various components leading to arterial thrombosis, and the effect of smoking cessation on prothrombotic state and platelet aggregation is still under investigation GOAL To assess rates of smoking cessation in patients after coronary angiography and PCI and factors influencing success in smoking cessation To assess feasibility, safety and efficacy of cytisine in smoking patients To assess effect of smoking cessation on platelet aggregation in patients treated with clopidogrel and on prothrombotic state.
METHODS A prospective nonrandomized observational study of patients after coronary angiography.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Switching From Cigarettes to Tobacco Heating System on Coronary Atherosclerosis Progression
NCT05660798
Evaluation of the Added Value of Sophrology on the Intensity of Craving During Smoking Withdrawal
NCT04700306
Early Smoking Reduction or Cessation by Means of no Nicotine Electronic Cigarette Added to Standard Counselling.
NCT01733706
Switching to E-cigarette After PCI
NCT06338761
Effects of Chronic Smoking on Circulating Endothelial and Platelet-derived Microparticle
NCT00795249
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged 18 years or older,
* Smoking at least 10 cigarettes a day
Exclusion Criteria
Criteria may vary in substudies
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre of Postgraduate Medical Education
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bogumil Ramotowski
MD, PhD, Adjunct, Director of the Programme
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
16/PB/2014
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.